GlassScriptPhysician profile
Rajiv Ranjan
NPI 1679520225
$935.63
in general payments reported to CMS, 2019-2025
21 companies · $50.70 in 2025
The $50.70 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $106 · 2021: $166 · 2022: $173 · 2023: $196 · 2024: $90.84 · 2025: $50.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $235.42 | 2021-2024 | Amplatzer Amulet, Cardiomems, Tacticath |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.52 | 2020-2025 | Lifevest |
| Medtronic Vascular, INC. | $82.57 | 2019-2020 | |
| Pfizer INC. | $75.81 | 2020-2024 | |
| Medtronic, INC. | $57.21 | 2021-2023 | Onyx Frontier |
| E.R. Squibb & Sons, L.L.C. | $55.41 | 2021-2023 | Camzyos |
| Penumbra, INC. | $44.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.40 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $28.24 | 2024 | Arcalyst |
| Chiesi USA, INC. | $27.88 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $23.20 | 2023 | Optimizer |
| Amarin Pharma, INC. | $19.60 | 2021 | |
| Teleflex LLC | $18.62 | 2024 | Guideliner |
| Amgen INC. | $16.61 | 2019 | |
| Terumo Medical Corporation | $14.96 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $14.47 | 2019 | |
| Daiichi Sankyo INC. | $13.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Ranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.